Illumina on Track for a $4 Billion Year

BIOTECH: 2021 Could Be Turning Point as Grail Matter Is Decided

⯀ By BRAD GRAVES
FRONT PAGE

Illumina Inc. (Nasdaq: ILMN) expects a $4 billion year in 2021. The gene sequencing specialist increased its financial guidance on April 5, saying it expects year-over-year revenue growth of 25% to 28% from the $3.24 billion that it brought in during...

Read latest San Diego Business Journal online.

Online newspapers at PressDisplay.